| Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in … M Nauck, A Frid, K Hermansen, NS Shah, T Tankova, IH Mitha, ... Diabetes care 32 (1), 84-90, 2009 | 1538 | 2009 |
| Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial A Garber, R Henry, R Ratner, PA Garcia-Hernandez, H Rodriguez-Pattzi, ... The Lancet 373 (9662), 473-481, 2009 | 1531 | 2009 |
| Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding … M Marre, J Shaw, M Brändle, WMW Bebakar, NA Kamaruddin, J Strand, ... Diabetic Medicine 26 (3), 268-278, 2009 | 1143 | 2009 |
| Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+ SU): a randomised controlled trial D Russell-Jones, A Vaag, O Schmitz, BK Sethi, N Lalic, S Antic, ... Diabetologia 52, 2046-2055, 2009 | 1032 | 2009 |
| Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+ TZD) B Zinman, J Gerich, JB Buse, A Lewin, S Schwartz, P Raskin, PM Hale, ... Diabetes care 32 (7), 1224-1230, 2009 | 1026 | 2009 |
| The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men H Agersø, LB Jensen, B Elbrønd, P Rolan, M Zdravkovic Diabetologia 45, 195-202, 2002 | 632 | 2002 |
| Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation L Bjerre Knudsen, LW Madsen, S Andersen, K Almholt, AS de Boer, ... Endocrinology 151 (4), 1473-1486, 2010 | 628 | 2010 |
| Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of … T Vilsbøll, M Zdravkovic, T Le-Thi, T Krarup, O Schmitz, JP Courreges, ... Diabetes care 30 (6), 1608-1610, 2007 | 623 | 2007 |
| A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir J Plank, M Bodenlenz, F Sinner, C Magnes, E Görzer, W Regittnig, ... Diabetes care 28 (5), 1107-1112, 2005 | 393 | 2005 |
| Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects B Elbrønd, G Jakobsen, S Larsen, H Agersø, LB Jensen, P Rolan, J Sturis, ... Diabetes care 25 (8), 1398-1404, 2002 | 364 | 2002 |
| Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result … J Jendle, MA Nauck, DR Matthews, A Frid, K Hermansen, M Düring, ... Diabetes, Obesity and Metabolism 11 (12), 1163-1172, 2009 | 329 | 2009 |
| Liraglutide, a once‐daily human GLP‐1 analogue, improves pancreatic B‐cell function and arginine‐stimulated insulin secretion during hyperglycaemia in patients with Type 2 … T Vilsbøll, B Brock, H Perrild, K Levin, HH Lervang, K Kølendorf, T Krarup, ... Diabetic Medicine 25 (2), 152-156, 2008 | 294 | 2008 |
| Effect of renal impairment on the pharmacokinetics of the GLP‐1 analogue liraglutide LV Jacobsen, C Hindsberger, R Robson, M Zdravkovic British journal of clinical pharmacology 68 (6), 898-905, 2009 | 258 | 2009 |
| Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes JP Courreges, T Vilsbøll, M Zdravkovic, T Le-Thi, T Krarup, O Schmitz, ... Diabetic Medicine 25 (9), 1129, 2008 | 245 | 2008 |
| GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese … L Hegedüs, AC Moses, M Zdravkovic, T Le Thi, GH Daniels The Journal of Clinical Endocrinology & Metabolism 96 (3), 853-860, 2011 | 220 | 2011 |
| Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes MA Nauck, M Hompesch, R Filipczak, TDT Le, M Zdravkovic, J Gumprecht Experimental and clinical endocrinology & diabetes 114 (08), 417-423, 2006 | 211 | 2006 |
| Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and … M Malm-Erjefält, I Bjørnsdottir, J Vanggaard, H Helleberg, U Larsen, ... Drug Metabolism and Disposition 38 (11), 1944-1953, 2010 | 205 | 2010 |
| Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes M Horowitz, A Flint, KL Jones, C Hindsberger, MF Rasmussen, C Kapitza, ... Diabetes research and clinical practice 97 (2), 258-266, 2012 | 191 | 2012 |
| Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber MU Zafar, DA Vorchheimer, J Gaztanaga, M Velez, D Yadegar, ... Thrombosis and Haemostasis 98 (10), 883-888, 2007 | 155 | 2007 |
| Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with … Y Seino, MF Rasmussen, M Zdravkovic, K Kaku Diabetes research and clinical practice 81 (2), 161-168, 2008 | 146 | 2008 |
